ViiV Healthcare: Comprehensive Company Profile

Background

Overview

ViiV Healthcare is a global pharmaceutical company dedicated exclusively to the research, development, and commercialization of medicines for the treatment and prevention of HIV/AIDS. Established in November 2009 as a joint venture between GlaxoSmithKline (GSK) and Pfizer, ViiV Healthcare's mission is to end the HIV epidemic and ensure no person living with HIV is left behind. In 2012, Shionogi joined as a shareholder, further strengthening the company's commitment to advancing HIV care.

Mission and Vision

ViiV Healthcare's mission is to deliver advances in HIV treatment and care, focusing on the needs of people living with HIV and those at risk of infection. The company's vision is to end the HIV and AIDS epidemic, ensuring no one living with HIV is left behind.

Primary Area of Focus

The company's primary focus is on developing innovative HIV therapies, including antiretroviral treatments and preventive measures, to improve the quality of life for individuals living with HIV worldwide.

Industry Significance

ViiV Healthcare holds a significant position in the global HIV treatment market, with its products accounting for approximately 32% of the global HIV therapy market share, making it the second-largest company in the sector after Gilead Sciences.

Key Strategic Focus

Core Objectives

Innovative Research and Development: Focus on developing new HIV treatments and preventive measures to address the evolving needs of patients.

Global Access to Medicines: Ensure that effective HIV treatments are accessible to individuals worldwide, particularly in low- and middle-income countries.

Community Engagement: Collaborate with communities affected by HIV to understand their needs and provide support through various programs.

Specific Areas of Specialization

Long-Acting HIV Therapies: Development of injectable treatments that reduce the frequency of dosing, improving adherence and quality of life for patients.

Pediatric HIV Treatments: Addressing the unique needs of children living with HIV through specialized formulations and treatment regimens.

Key Technologies Utilized

Long-Acting Injectable Formulations: Innovative drug delivery systems that allow for less frequent dosing, enhancing patient convenience and adherence.

Collaborative Research Platforms: Partnerships with academic institutions, non-governmental organizations, and other stakeholders to accelerate HIV research and development.

Primary Markets Targeted

Global HIV Treatment Market: Serving individuals living with HIV worldwide, with a particular focus on regions with high HIV prevalence.

Low- and Middle-Income Countries: Ensuring access to HIV treatments in resource-limited settings through pricing strategies and partnerships.

Financials and Funding

Funding History

ViiV Healthcare was established as a joint venture between GSK and Pfizer, with Shionogi joining in 2012. The company has received substantial investment from its parent companies to support its research and development initiatives.

Total Funds Raised

Specific figures regarding total funds raised are not publicly disclosed.

Recent Funding Rounds

Details of recent funding rounds are not publicly available.

Notable Investors

GlaxoSmithKline (GSK): Holds a 76.5% stake in ViiV Healthcare.

Pfizer: Holds a 13.5% stake in ViiV Healthcare.

Shionogi: Holds a 10% stake in ViiV Healthcare.

Intended Utilization of Capital

The capital is primarily utilized for:

Research and Development: Advancing the pipeline of HIV treatments and preventive measures.

Global Access Programs: Implementing initiatives to make HIV treatments accessible in low- and middle-income countries.

Community Engagement: Supporting programs that address the needs of communities affected by HIV.

Pipeline Development

Key Pipeline Candidates

S-365598: A third-generation investigational integrase strand transfer inhibitor (INSTI) with potential for ultra long-acting dosing intervals. ViiV Healthcare has an exclusive collaboration and license agreement with Shionogi for this compound.

Stages of Clinical Trials or Product Development

S-365598: Preclinical studies are underway, with plans to initiate first-time-in-human studies by 2023.

Target Conditions

S-365598: HIV-1 infection, with a focus on providing ultra long-acting treatment options.

Relevant Timelines for Anticipated Milestones

S-365598: First-time-in-human studies anticipated to begin by 2023.

Technological Platform and Innovation

Proprietary Technologies

Long-Acting Injectable Formulations: Development of injectable HIV treatments that reduce dosing frequency, enhancing patient adherence.

Significant Scientific Methods

Implementation Science Studies: Conducting studies like the CARISEL study to evaluate the integration of long-acting HIV treatments into clinical practice.

Leadership Team

Key Executive Profiles

Deborah Waterhouse: Chief Executive Officer (CEO) of ViiV Healthcare. She has been leading the company since April 2017, succeeding Dominique Limet.

Kimberly Smith, M.D., MPH: Head of Research & Development at ViiV Healthcare. She has been instrumental in advancing the company's pipeline of HIV treatments.

Competitor Profile

Market Insights and Dynamics

The global HIV treatment market is valued at approximately £19.7 billion, with a projected annual growth rate of 13.5%. ViiV Healthcare holds a 13% market share, positioning it as the second-largest company in the sector after Gilead Sciences.

Competitor Analysis

Gilead Sciences: The leading company in the HIV treatment market, holding a 60% market share.

Other Competitors: Companies such as AbbVie, Merck, and Johnson & Johnson's Janssen division also participate in the HIV treatment market, each holding smaller market shares.

Strategic Collaborations and Partnerships

Shionogi: Collaborated with ViiV Healthcare to develop S-365598, a third-generation INSTI with potential for ultra long-acting dosing intervals.

Janssen Pharmaceuticals: Partnered with ViiV Healthcare to develop the first long-acting, two-drug injectable regimen for the treatment of HIV-1 infection.

Operational Insights

ViiV Healthcare's focus on long-acting injectable therapies differentiates it from competitors by offering treatment options that reduce dosing frequency, potentially improving patient adherence and quality of life.

Strategic Opportunities and Future Directions

ViiV Healthcare aims to expand its portfolio of long-acting HIV treatments, enhance global access to its medicines, and strengthen collaborations with community organizations to address the diverse needs of individuals living with HIV.